New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
07:20 EDTKPTIKaryopharm price target raised to $50 from $25 at JMP Securities
JMP Securities raised its price target on Karyopharm after it provided an outline of planned pivotal trials in AML, DLBCL, and Richterís syndrome, and formally stated that it is broadening its Phase II development plans in various solid tumor malignancies. The firm sees unmet need in these indications and its confidence in the company's chances of success has increased. It increased its estimate of peak U.S. sales for selinexor to $3.6B from $1.8B and reiterates an Outperform rating.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
10:04 EDTKPTIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:27 EDTKPTIKaryopharm initiates clinical study of Selinexor
Subscribe for More Information
07:26 EDTKPTIKaryopharm sees existing cash, cash equivalents to fund R&D into 2H17
Karyopharm expects to end 2014 with greater than $200M in cash and cash equivalents.
07:26 EDTKPTIKaryopharm reports Q3 EPS (61c), consensus (52c)
Subscribe for More Information
07:18 EDTKPTIKaryopharm upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use